pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 23·1 min read
save

Endpoints News earns three Neal Awards for Trump coverage, CRISPR series and JPM event

Apr 23, 2026·read at Endpoints ↗Positive

Endpoints News was honored with three Neal Awards in 2026.

The awards recognize its reporting on the pharmaceutical industry's interactions with the Trump administration, a three-part series exploring the future of CRISPR gene-editing technology, and coverage of a recent JPMorgan event.

The accolades highlight the outlet's focus on policy, scientific innovation and industry events, underscoring its role as a leading source of pharma news.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event”

read at Endpoints ↗
104 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
topics
CRISPR/Cas94

related stories

  • 2d agoFoghorn cuts 40% of workforceBioSpace
  • Sep 23ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s handsBioSpace
  • Sep 14Cellectis quits CAR-T and pivots to ‘in vivo’ gene editingBioPharma Dive
  • Sep 14Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonFierce Biotech
  • Aug 10Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the massesBioPharma Dive